Skip to contentS
Spyre Therapeutics, Inc.
S
SYRESpyre Therapeutics, Inc. Q1 2025 · 10-Q
Revenue—
Net Income-$44.77M-$44.77MN/M vs Q1 2024 EPS, diluted—
Operating Income-$53,567,000N/M Operating Cash Flow-$40,994,000N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spyre Therapeutics, Inc. · CIK 1636282 · Engraved from SEC EDGAR
ended Mar 31, 2025 · filed May 8, 2025 · 38 d after period end